AL Amyloidosis Bispecific Trial: Who Qualifies, Response , Side Effects & Organ Response | IMS 2026

Giada Bianchi, MD, of Dana-Farber Cancer Institute discusses interim results from a phase 1/2 trial of elranatamab in relapsed light chain (AL) amyloidosis at IMS 2026 in Glasgow. Bispecific antibodies are approved for relapsed myeloma but had not been prospectively studied in AL amyloidosis. In the first 11 patients, this BCMA bispecific produced rapid, deep and lasting responses with mostly mild side effects. She also covers early signs of heart and kidney improvement and the six-month fixed-duration design.

If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity

Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general

Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.

Timestamps:

0:00 Introduction: Dr. Giada Bianchi, Dana-Farber Cancer Institute

0:22 Trial Overview and How Bispecific T-Cell Engagers Work

1:22 Patient Eligibility: Prior Treatment and Exclusion Criteria

2:16 Results: Universal and Deep Responses

3:09 Side Effects: Cytokine Release Syndrome and Infection Risk

4:24 Organ Response and the Fixed Six-Month Design

5:39 Q&A: Can Myeloma Patients Join This Trial?